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dear Editor,
i have noticed a possibly coincidental, but intrigu-
ing issue, previously investigated by some authors, 
which i would like to re-actualize and share with he-
matological community as an impulse for future in-
vestigations and potential clinical trials.
Among 29 patients of mine with the diagnosis of 
JAK2-V617f positive chronic myeloproliferative neo-
plasm (Cmpn), including polycythemia vera (pV), 
essential thrombocythemia (ET) and idiopathic my-
elofibrosis, two of them developed monoclonal gam-
mopathy of undetermined significance (mgus), 
which seems to be a higher frequency than expected 
in the general Caucasian population.
Patient 1: A Caucasian female, diagnosis of pV 
was established in 1997, according to the person-mes-
sinazy’s criteria1, when she was 65. she was treated 
with periodical venesections, aspirin and hydroxycar-
bamide (hC). Later on, JAK2-V617f mutation was 
proven. in 2007, she transformed into myelofibrosis 
and mgus, igg lambda, was diagnosed using the 
international myeloma Working group criteria2. The 
patient died in 2011 due to myelofibrosis progression.
Patient 2: A Caucasian male, diagnosis of pV was 
established in 1997, when he was 55. he was treated 
in the same way as patient 1, with periodical vene-
sections, aspirin and hC. during the course of dis-
ease, JAK2-V617f mutation was confirmed. The di-
agnosis of mgus, igg kappa, was made in 2009. The 
same diagnostic criteria for pV and mgus were used. 
The patient is stable and under control, there has been 
no progression/transformation of pV or mgus.
This observation on a very small group of patients 
cannot be a basis for any conclusions. however, the 
metachronous development of mgus in patients 
with long-lasting JAK2-V617f positive pV (Cmpn) 
treated with hC for years, can implicate several ques-
tions:
1. Can the long-lasting use of hC increase the in-
cidence of mgus in patients with pV (Cmpn)?
2. Can the JAK2-V617f mutation somehow be 
involved in the pathogenesis of mgus in such pa-
tients?
3. is it possible that bone marrow fibrosis, which 
appears and progresses during the biological course 
of pV (Cmpn), may promote the development of 
monoclonal plasma cells due to changes in bone mar-
row microenvironment, especially fibroblast activity? 
4. finally, is the risk of mgus development high-
er in patients with pV (Cmpn) than in the general 
population?
some authors have described patients with Cmpn 
treated with hC who finally developed plasma cell 
dyscrasias or other hematologic neoplasms3,4, but until 
now there has been no clear association between the 
use of hC and an increased risk of developing sec-
ond hematologic malignancies. in their retrospective 
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analysis, radaelli et al. found that patients with ET 
treated with hC did not have an increased risk of sec-
ond hematologic tumors5. still, the possible oncoge-
netic potential of hC remains a matter of debate.
it is well known that JAK2/sTAT pathway plays 
a role in myeloma pathogenesis6,7. furthermore, some 
of the JAK2 tyrosine kinase inhibitors have shown 
significant anti-myeloma activity7,8. on the other 
hand, fiorini et al. did not find the presence of JAK2-
V617f mutation in their sample of myeloma patients9. 
Taken together, further investigation of JAK2/sTAT 
pathway, as well as mutational screening of JAK2 
coding exons, are warranted in plasma cell dyscrasias. 
randi et al. have already investigated the association 
of mgus and pV/ET in their retrospective studies. 
They found a higher incidence of mgus in pV/ET 
patients compared to control patients, although with-
out any statistical significance10,11. Economopoulos et 
al. and berner and berrebi also noticed a potential 
connection between Cmpn and mgus12,13. how-
ever, these studies are not recent. new knowledge of 
the pathogenesis of Cmpn, especially the finding of 
JAK-2 mutations, implicates the necessity of larger, 
prospective, well designed trials to find the so far 
missing association between Cmpn and mgus. 
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